Analysis of RNA Polymerase II Mutants using Roche´s
October 22, 2009 08:00 AM Eastern Daylight Time
PENZBERG, Germany--(EON: Enhanced Online News)--The C-terminal domain (CTD) of RNA Polymerase II consists of multip
evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. T
the first description of the RNA polymerase II C-terminal domain, its function is still unclear. In a recent research study, M. Heidem
(Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) xCELLigence RTCA SP Instrument for in vitro testing of cells to test entirely syn
According to his findings, the new xCELLigence System technology allows for the first time the monitoring of cell proliferation and c
throughout the entire experiment, constantly recording cellular effects during cell plating, transfection, and compound treatment. This
continuous monitoring of cells provides a far more detailed picture into the whole experimental process, revealing both specific and
that may have been missed using conventional endpoint assays.
The precise regulation of gene expression is a very important feature of how organisms respond to environmental changes and regul
proliferation, development, and even programmed cell death. Gene expression starts with the transcription of genomic DNA into me
template for protein synthesis during ribosomal translation. RNA polymerase Pol II is one out of three different RNA polymerases u
cells to produce the main categories of cellular RNA. In contrast to Pol I and Pol III, Pol II transcripts are translated into proteins.
modified by enzymes influencing different stages of transcription, processing of premature mRNAs in a promoter-dependent manner
modifications occur in a domain at the carboxy-terminal part of the largest subunit of Pol II, which has a very unique structure.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals
Roche is th